ALCAM and neoplasm: Unlike what was observed for CD6, confronting PBMCs with tumor cell lines does not modify CD5 expression on immune cells (Figure 5C), which suggests that despite its high structural homology with CD6, neither CD318 nor ALCAM had an impact on CD5 expression.